$AKBA
Akebia Therapeutics, Inc. Stock $akba

$akba Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023016258 Filed on May 08, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$56.38M	$40.13M
YoY Change	-55.53%	-34.96%
Cost Of Revenue	$17.28M	$19.48M
YoY Change	-7.08%	-37.84%
Gross Profit	$39.09M	$20.64M
YoY Change	-63.86%	-31.99%
Gross Profit Margin	69.34%	51.44%
Selling, General & Admin	$27.04M	$25.22M
YoY Change	-17.59%	-43.1%
% of Gross Profit	69.16%	122.18%
Research & Development	$20.20M	$19.69M
YoY Change	-22.4%	-55.09%
% of Gross Profit	51.67%	95.36%
Depreciation & Amortization	$9.011M	$9.409M
YoY Change	-4.4%	-0.2%
% of Gross Profit	23.05%	45.58%
Operating Expenses	$48.09M	$45.58M
YoY Change	-35.24%	-48.7%
Operating Profit	-$8.996M	-$24.94M
YoY Change	-126.54%	-57.37%
Interest Expense	-$1.642M	-$1.561M
YoY Change	-67.4%	-69.16%
% of Operating Profit
Other Income/Expense, Net	-$10.00K	$282.0K
YoY Change	-102.43%	-75.13%
Pretax Income	-$11.17M	-$26.22M
YoY Change	-138.16%	-58.0%
Income Tax
% Of Pretax Income
Net Earnings	-$11.17M	-$26.22M
YoY Change	-138.16%	-58.0%
Net Earnings / Revenue	-19.82%	-65.34%
Basic Earnings Per Share	-$0.06	-$0.14
Diluted Earnings Per Share	-$0.06	-$0.14
COMMON SHARES
Basic Shares Outstanding	185.9M shares	184.2M shares
Diluted Shares Outstanding	186.8M shares	184.8M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.57M	$56.95M
YoY Change	-62.77%	-67.37%
Cash & Equivalents	$53.57M	$57.00M
Short-Term Investments
Other Short-Term Assets	$24.40M	$25.38M
YoY Change	-42.09%	5.22%
Inventory	$20.91M	$20.60M
Prepaid Expenses	$15.60M
Receivables	$19.57M	$17.78M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$118.4M	$120.7M
YoY Change	-61.06%	-60.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.419M	$4.816M
YoY Change	-26.78%	-25.34%
Goodwill	$59.00M	$55.10M
YoY Change	7.08%	0.0%
Intangibles	$54.06M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.348M	$5.238M
YoY Change	-90.42%	-86.71%
Total Long-Term Assets	$135.3M	$156.1M
YoY Change	-37.85%	-32.89%
TOTAL ASSETS
Total Short-Term Assets	$118.4M	$120.7M
Total Long-Term Assets	$135.3M	$156.1M
Total Assets	$253.7M	$276.9M
YoY Change	-51.38%	-48.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.78M	$12.58M
YoY Change	-52.79%	-35.39%
Accrued Expenses	$56.41M	$46.37M
YoY Change	-38.21%	-57.72%
Deferred Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$24.00M	$24.00M
YoY Change	-75.55%	-75.47%
Total Short-Term Liabilities	$92.18M	$82.94M
YoY Change	-60.55%	-67.33%
LONG-TERM LIABILITIES
Long-Term Debt	$18.49M	$26.30M
YoY Change
Other Long-Term Liabilities	$17.14M	$12.64M
YoY Change	-74.37%	-83.74%
Total Long-Term Liabilities	$35.63M	$38.94M
YoY Change	-46.74%	-49.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.18M	$82.94M
Total Long-Term Liabilities	$35.63M	$38.94M
Total Liabilities	$280.5M	$291.2M
YoY Change	-38.95%	-42.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.595B	-$1.579B
YoY Change	6.8%	3.7%
Common Stock	$1.568B	$1.565B
YoY Change	0.8%	1.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$26.81M	-$14.35M
YoY Change
Total Liabilities & Shareholders Equity	$253.7M	$276.9M
YoY Change	-51.38%	-48.29%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$11.17M	-$26.22M
YoY Change	-138.16%	-58.0%
Depreciation, Depletion And Amortization	$9.011M	$9.409M
YoY Change	-4.4%	-0.2%
Cash From Operating Activities	$3.629M	-$17.54M
YoY Change	-111.84%	-18.88%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-8.000M	-$15.97M
YoY Change	88788.89%	-133.58%
NET CHANGE
Cash From Operating Activities	3.629M	-$17.54M
Cash From Investing Activities	0.000	$0.00
Cash From Financing Activities	-8.000M	-$15.97M
Net Change In Cash	-4.371M	-$33.50M
YoY Change	-85.75%	-229.81%
FREE CASH FLOW
Cash From Operating Activities	$3.629M	-$17.54M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	$3.629M	-$17.54M
YoY Change	-111.84%	-19.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001517022
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36352
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AKEBIA THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8756903
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	245 First Street
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	871-2098
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.00001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	AKBA
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	185928121	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56953000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90466000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	20604000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	21762000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17781000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39180000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	25381000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33541000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	120719000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	184949000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4816000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5214000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27958000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29158000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	55053000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	55053000	usd
CY2023Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	63074000	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	72084000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5238000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5372000	usd
CY2023Q1	us-gaap	Assets Assets	276858000	usd
CY2022Q4	us-gaap	Assets Assets	351830000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	12577000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18021000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46367000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	70997000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3738000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	24000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	32000000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	82944000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	124756000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43296000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43296000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27418000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28961000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	760000	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	760000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26296000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34078000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	57059000	usd
CY2022Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	57484000	usd
CY2023Q1	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	40794000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability Noncurrent ContractWithCustomerRefundLiabilityNoncurrent	40992000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12643000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12161000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	291210000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	342488000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185835946	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185835946	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184135714	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184135714	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1564770000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1562247000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1579130000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1552913000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14352000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9342000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276858000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	351830000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40127000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	61699000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	10473000	usd
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	22333000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	9011000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	19484000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	31344000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19686000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43833000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25221000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44327000	usd
CY2023Q1	akba	License Expense LicenseExpense	568000	usd
CY2022Q1	akba	License Expense LicenseExpense	688000	usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges	106000	usd
CY2022Q1	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	45581000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	88848000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24938000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-58493000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1561000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5062000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	282000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1134000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26217000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-26217000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-62421000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-62421000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184768983	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	184768983	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	179599045	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	179599045	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26217000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26217000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62421000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	76456000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7178000	usd
CY2022Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	367000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4536000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	26116000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9342000	usd
CY2023Q1	akba	Stock Issued During Period Value Including Offering Costs Employee Stock Purchase Plan StockIssuedDuringPeriodValueIncludingOfferingCostsEmployeeStockPurchasePlan	34000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2489000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26217000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14352000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26217000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	5344000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-62421000	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	398000	usd
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	417000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9011000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9011000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	0	usd
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Noncash Interest Expense Income ContractualArrangementRoyaltiesAgreementNoncashInterestExpenseIncome	2345000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	425000	usd
CY2022Q1	akba	Contractual Arrangement Royalties Agreement Noncash Royalty Revenue ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue	329000	usd
CY2023Q1	akba	Noncash Research And Development Expense NoncashResearchAndDevelopmentExpense	782000	usd
CY2022Q1	akba	Noncash Research And Development Expense NoncashResearchAndDevelopmentExpense	0	usd
CY2023Q1	akba	Noncash Interest Expense NoncashInterestExpense	502000	usd
CY2022Q1	akba	Noncash Interest Expense NoncashInterestExpense	246000	usd
CY2023Q1	us-gaap	Straight Line Rent StraightLineRent	578000	usd
CY2022Q1	us-gaap	Straight Line Rent StraightLineRent	557000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	335000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57000000	usd
CY2023Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	0	usd
CY2022Q1	akba	Excess Inventory Purchase Commitments Expense Reversal ExcessInventoryPurchaseCommitmentsExpenseReversal	-773000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2489000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4536000	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-710000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-21399000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13707000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7347000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5247000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7378000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9019000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2812000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3297000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9013000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7358000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-25047000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4426000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	651000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	616000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3738000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	33416000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-3191000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17538000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21620000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-114000	usd
CY2023Q1	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	0	usd
CY2022Q1	akba	Proceeds From Refund Liability To Contract With Customer ProceedsFromRefundLiabilityToContractWithCustomer	40000000	usd
CY2023Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0	usd
CY2022Q1	akba	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	7178000	usd
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	34000	usd
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	367000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	16000000	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15966000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47545000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33504000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25811000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93169000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	151839000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59665000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177650000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Organization and Operations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Akebia Therapeutics, Inc., referred to as Akebia or the Company, was incorporated in the State of Delaware in 2007. Akebia is a fully integrated biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease. The Company has one commercial product, Auryxia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ferric citrate), which is approved by the U.S. Food and Drug Administration, or FDA, and marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with chronic kidney disease, or CKD, on dialysis, or DD-CKD, and the treatment of iron deficiency anemia, or IDA, in adult patients with CKD not on dialysis, or NDD-CKD. Ferric citrate is also approved and marketed in Japan as an oral treatment for IDA in adult patients for the improvement of hyperphosphatemia in such patients with DD-CKD and NDD-CKD under the trade name Riona (ferric citrate hydrate).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vadadustat, the Company’s lead investigational product candidate, is an investigational oral hypoxia-inducible factor prolyl hydroxylase, or HIF-PH, inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. On March 29, 2022, the Company received a complete response letter, or CRL, from the FDA. The CRL provided that the FDA had completed its review of the Company's new drug application, or NDA, for vadadustat for the treatment of anemia due to CKD in adult patients and had determined that it could not approve the NDA in its present form. In October 2022, the Company submitted a Formal Dispute Resolution Request, or FDRR, with the FDA. The FDRR focused on the favorable balance between the benefits and risks of vadadustat for the treatment of anemia due to CKD in adult DD-CKD patients in light of safety concerns expressed by the FDA in the CRL for dialysis patients related to the rate of adjudicated thromboembolic events driven by vascular access thrombosis for vadadustat compared to the active comparator and the risk of drug-induced liver injury. In February 2023, the Company received a second interim response from the FDA to the FDRR. In March 2023, the Company had a productive meeting with the FDA, who indicated that it was continuing internal consultation with experts to complete the review and render a decision. FDA has indicated that it has completed internal discussions, and the Company expects a response to the FDRR within the next thirty days. In October 2021, the Company's former collaboration partner, Otsuka Pharmaceutical Co. Ltd., or Otsuka, submitted a Marketing Authorization Application, or MAA, for vadadustat for the treatment of anemia due to CKD in adult patients with DD-CKD and NDD-CKD to the European Medicines Agency, or EMA</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Termination and Settlement Agreement with Otsuka dated June 30, 2022, or the Termination Agreement, Otsuka transferred the MAA for vadadustat with the EMA to the Company. In April 2023, the European Commission, or EC, approved the marketing authorization of vadadustat under the trade name Vafseo™ for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. Vadadustat is approved in Japan as a treatment for anemia due to CKD in both DD-CKD and NDD-CKD patients under the trade name Vafseo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and marketed and sold in Japan by Mitsubishi Tanabe Pharma Corporation, or MTPC. Vadadustat is also approved in Korea as a treatment for anemia due to CKD in DD-CKD patients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Company continues to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted most of its resources to research and development, including its preclinical and clinical development activities, commercializing Auryxia, and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company’s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively JT and Torii, in December 2018. Additionally, following regulatory approval of vadadustat in Japan, the Company began recognizing royalty revenues from MTPC from the sale of Vafseo in August 2020. In February 2021, the Company entered into a royalty interest acquisition agreement with HealthCare Royalty Partners IV, L.P., or HCR, or the Royalty Agreement, whereby the Company sold its right to receive royalties and sales milestones under its Collaboration Agreement with MTPC, or the MTPC Agreement, subject to certain caps and other terms and conditions (see Note 5 for additional information). The Company has not generated a profit to date, and may never generate profits, from product sales. Vadadustat and the Company’s other potential product candidates are subject to long development cycles, and the Company may be unsuccessful in its efforts to develop, obtain marketing approval for or market vadadustat and its other potential product candidates. If the Company does not successfully commercialize Auryxia, vadadustat, if approved, or any other potential product candidate, it may be unable to achieve profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company’s management completed its going concern assessment in accordance with Accounting Standards Codification, or ASC, 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, or ASC 205-40. As of March 31, 2023, the Company had cash and cash equivalents of approximately $57.0 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on its current operating plan, the Company believes that its cash resources will be sufficient to allow the Company to fund its current operating plan </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">through at least the next twelve months from the filing of this Quarterly Report on Form 10-Q. If the Company’s operating performance deteriorates significantly from the levels expected in the Company’s operating plan, it could have an effect on the Company’s liquidity and its ability to continue as a going concern in the future. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects to finance future cash needs through product revenue, potential strategic transactions, public or private equity or debt transactions, operating expense management, or a combination of these approaches. Assuming the Company is successful in executing its operating plan, the Company will require additional funding to fund its strategic growth beyond Auryxia or to pursue later stage development and commercial activities for its product candidates and any additional product or product candidates, including those that may be in-licensed or acquired. There can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, or that its cash resources will fund its operating plan for the period anticipated by the Company, or that additional funding will be available on terms acceptable to the Company, or at all.</span>
CY2023Q1	akba	Number Of Commercial Products NumberOfCommercialProducts	1	commercial_product
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: prepaid and accrued research and development expense, operating lease assets and liabilities, derivative liabilities, refund liabilities to customers, other non-current liabilities, stock-based compensation expense, product and collaboration revenues including various rebates and reserves related to product sales, non-cash interest expense on the liability related to sale of future royalties, inventories, income taxes, intangible assets and goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.</span></div>
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	31353000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	20151000	usd
CY2023Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	-1748000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	25949000	usd
CY2023Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	23807000	usd
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	28378000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	25394000	usd
CY2022Q1	akba	Valuation Allowances And Reserves Adjustments Related To Prior Period Sales ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales	647000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	26249000	usd
CY2022Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	28170000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	43296000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	43296000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3738000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6602000	usd
CY2023Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2022Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
CY2023Q1	akba	Contract With Customer Refund Liability Amortization Of Discount ContractWithCustomerRefundLiabilityAmortizationOfDiscount	800000	usd
CY2022Q1	akba	Contract With Customer Refund Liability Amortization Of Discount ContractWithCustomerRefundLiabilityAmortizationOfDiscount	0	usd
CY2023Q1	akba	Contract With Customer Refund Liability Amortization Of Deferred Gain ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain	1000000	usd
CY2022Q1	akba	Contract With Customer Refund Liability Amortization Of Deferred Gain ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain	0	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity	13000000	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity	150000000	usd
CY2021Q1	akba	Proceeds From Contractual Arrangement Royalties Agreement Sale Of Future Royalties ProceedsFromContractualArrangementRoyaltiesAgreementSaleOfFutureRoyalties	44800000	usd
CY2021Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	44800000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage	0
CY2022Q4	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	57484000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Royalties Earned And Payable ContractualArrangementRoyaltiesAgreementRoyaltiesEarnedAndPayable	425000	usd
CY2023Q1	akba	Contractual Arrangement Royalties Agreement Liability Noncurrent ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent	57059000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	760000	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	760000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	503000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	610000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8100000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8086000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12504000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13676000	usd
CY2023Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	21107000	usd
CY2022Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	22372000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	20604000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	21762000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	503000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	610000	usd
CY2023Q1	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	21107000	usd
CY2022Q4	akba	Inventory Net Current And Non Current InventoryNetCurrentAndNonCurrent	22372000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	300000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	5300000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	150529000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	63074000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	213603000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	141519000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	72084000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	55100000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	55100000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	22368000	usd
CY2022Q4	akba	Accrued Product Revenue Allowances Current AccruedProductRevenueAllowancesCurrent	29005000	usd
CY2023Q1	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1148000	usd
CY2022Q4	akba	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	5755000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5717000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11481000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5160000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4744000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2636000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3804000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1621000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1734000	usd
CY2023Q1	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	1299000	usd
CY2022Q4	akba	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	4310000	usd
CY2023Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1286000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2751000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5132000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7413000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	46367000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	70997000	usd
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185835946	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	185835946	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	184135714	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	184135714	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	akba	Number Of Stock Incentive Plans NumberOfStockIncentivePlans	1	stock_incentive_plan
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	1800000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1800000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5248000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8162000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8289000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6132000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2570000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9631000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40032000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	40032000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7452000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	32580000	usd
CY2023Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	77600000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20573488	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19970534	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-23-016258-index-headers.html	Edgar Link	pending
0001628280-23-016258-index.html	Edgar Link	pending
0001628280-23-016258.txt	Edgar Link	pending
0001628280-23-016258-xbrl.zip	Edgar Link	pending
akba-20230331.htm	Edgar Link	pending
akba-20230331.xsd	Edgar Link	pending
exhibit101-amendedandresta.htm	Edgar Link	pending
akba-20230331_cal.xml	Edgar Link	unprocessable
akba-20230331_lab.xml	Edgar Link	unprocessable
akba-20230331_pre.xml	Edgar Link	unprocessable
akba-20230331_def.xml	Edgar Link	unprocessable
akba-20230331_htm.xml	Edgar Link	completed
exhibit102-akebiasiegfried.htm	Edgar Link	pending
exhibit103-formofakebia201.htm	Edgar Link	pending
exhibit311-q12023.htm	Edgar Link	pending
exhibit312-q12023.htm	Edgar Link	pending
exhibit321-q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AKBA
Akebia Therapeutics, Inc. Stock $akba

2023 Q2 Form 10-Q Financial Statement

#000162828023016258 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA Akebia Therapeutics, Inc. Stock $akba

2023 Q2 Form 10-Q Financial Statement

#000162828023016258 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AKBA
Akebia Therapeutics, Inc. Stock $akba